Prostate-specific antigen and radiation therapy for clinically localized prostate cancer

International Journal of Radiation Oncology, Biology, Physics
G K ZagarsAndrew C von Eschenbach

Abstract

This study was undertaken to: (a) define the prognostic significance of pretreatment serum prostate-specific antigen (PSA) levels in localized prostate cancer treated with radiation; (b) define the prognostic usefulness of postradiation PSA levels; (c) evaluate the outcome of radiation using PSA as an endpoint. Disease outcome in 707 patients with Stages T1 (205 men), T2 (256 men), T3 (239 men), and T4 (7 men), receiving definitive external radiation as sole therapy, was evaluated using univariate and multivariate techniques. At a mean follow-up of 31 months, 157 patients (22%) developed relapse or a rising PSA. Multivariate analysis revealed pretreatment PSA level to be the most significant prognostic factor, with lesser though significant contributions due to Gleason grade (2-6 vs. 7-10) and transurethral resection in T3/T4 disease. The following four prognostic groupings were defined: group I, PSA < or = 4 ng/ml, any grade; group II, 4 < PSA < or = 20, grades 2-6; group III, 4 < PSA < or = 20, grades 7-10; group IV, PSA > 20, any grade. Five-year actuarial relapse rates in these groups were: I, 12%; II, 34%; III, 40%; and IV, 81%. Posttreatment nadir PSA was an independent determinant of outcome and only patients with nadir ...Continue Reading

References

Jan 1, 1992·International Journal of Radiation Oncology, Biology, Physics·G K Zagars
Aug 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M A RitterT J Kinsella
Dec 1, 1988·The Journal of Urology·B A Lowe, M B Listrom
Jan 1, 1988·Acta Oncologica·H R WithersB Maciejewski
Sep 30, 1994·International Journal of Radiation Oncology, Biology, Physics·V S KavadiA Pollack
Apr 30, 1995·International Journal of Radiation Oncology, Biology, Physics·A PollackS Kopplin
Apr 30, 1995·International Journal of Radiation Oncology, Biology, Physics·G K ZagarsM E Sands
Nov 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T M PisanskyJ E Oesterling
Mar 1, 1994·La Revue du praticien·F Eschwège, P Wibault
Mar 1, 1994·International Journal of Radiation Oncology, Biology, Physics·M D GauwitzG K Zagars
Nov 15, 1993·Cancer·R P Gibbons

❮ Previous
Next ❯

Citations

Aug 1, 1996·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·A L ZietmanW U Shipley
Feb 1, 1996·International Journal of Radiation Oncology, Biology, Physics·A PollackI I Rosen
May 1, 1996·International Journal of Radiation Oncology, Biology, Physics·A Pollack, G K Zagars
Jan 1, 1996·Urologic Oncology·C N Coleman, M A Stevenson
Mar 9, 2005·International Journal of Radiation Oncology, Biology, Physics·Steven J FeigenbergAlan Pollack
Jul 1, 1997·Urology·G E HanksB Movsas
May 1, 1999·Urology·J D SlaterJ M Slater
Dec 6, 2000·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·L J Denis
Dec 6, 2000·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·D C Beyer, D G Brachman
Oct 23, 1997·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·G K Zagars, A Pollack
Apr 18, 2002·International Journal of Radiation Oncology, Biology, Physics·Joseph M KaminskiGerald E Hanks
Dec 31, 2003·International Journal of Radiation Oncology, Biology, Physics·Scott G WilliamsGillian M Duchesne
Oct 1, 1996·International Journal of Radiation Oncology, Biology, Physics·E M HorwitzA A Martinez
Oct 1, 1996·International Journal of Radiation Oncology, Biology, Physics·R E Peschel
Feb 1, 1997·International Journal of Radiation Oncology, Biology, Physics·D C Beyer, J B Priestley
May 1, 1997·International Journal of Radiation Oncology, Biology, Physics·S P LankfordG K Zagars
Jul 15, 1997·International Journal of Radiation Oncology, Biology, Physics·C I SartorH M Sandler
Jun 1, 1997·International Journal of Radiation Oncology, Biology, Physics·J P LattanziG E Hanks
Mar 15, 1997·International Journal of Radiation Oncology, Biology, Physics·M S AnscherM W Dewhirst
Dec 10, 1997·International Journal of Radiation Oncology, Biology, Physics·P R AndersonG E Hanks
Oct 27, 1998·International Journal of Radiation Oncology, Biology, Physics·J D SlaterJ M Slater
Mar 17, 1999·International Journal of Radiation Oncology, Biology, Physics·A V D'AmicoJ P Richie

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.